HomeAI · summaries
Storia in 3 fonti
Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera
The FDA has approved Takeda’s Mimrylo (rusfertide) for polyc | The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
- ·
morningstar.com
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
